Trial Profile
A Randomized, Double-blind, Dose-escalation Clinical Trial of the Safety, Reactogenicity and Immunogenicity of MTBVAC Compared to BCG Vaccine SSI, in Newborns Living in a Tuberculosis Endemic Region With a Safety Arm in Adults
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs MTBVAC (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- Sponsors Biofabri
- 30 Apr 2018 Status changed from active, no longer recruiting to completed.
- 26 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 Sep 2017.
- 23 Sep 2016 Planned End Date changed from 1 Jan 2017 to 1 Jun 2017.